Transcutaneous Electrical Muscle Stimulation In Chronic Obstructive Pulmonary Disease (COPD)

April 10, 2013 updated by: Mitja Lainščak, The University Clinic of Pulmonary and Allergic Diseases Golnik

Transcutaneous Electrical Muscle Stimulation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Transcutaneous electrical muscle stimulation (TCEMS) is well established intervention for rehabilitation of clinically stable patients with chronic obstructive pulmonary disease.

The investigators have conceived this study to test whether TCEMS is feasible and tolerated by patients experiencing severe physical and psychical challenge of acutely exacerbated COPD.

Study Overview

Study Type

Interventional

Enrollment (Actual)

19

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Golnik, Slovenia, SI-4204
        • University Clinic Golnik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • chronic obstructive pulmonary disease GOLD stage III or IV
  • acute exacerbation of the disease

Exclusion Criteria:

  • contraindications for transcutaneous electrical muscle stimulation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TCEMS
Patients who will receive transcutaneous electrical muscle stimulation
On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Scores on the feasibility scale
Time Frame: 10 days (avarage time from admission to discharge)
Patients will be followed from admission until discharge
10 days (avarage time from admission to discharge)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Scores on the patient satisfaction scale
Time Frame: 10 days (avarage time from admission to discharge)
Patients will be followed from admission until discharge
10 days (avarage time from admission to discharge)
Number of patients with adverse events as a measure of Safety and tolerability
Time Frame: 10 days (avarage time from admission to discharge)
Patients will be followed from admission until discharge
10 days (avarage time from admission to discharge)
Health related quality of life on the St. George respiratory questionnaire
Time Frame: 10 days (avarage time from admission to discharge)
Patients will be followed from admission until discharge
10 days (avarage time from admission to discharge)
Dyspnea on the MRC dyspnea scale
Time Frame: 10 days (avarage time from admission to discharge)
Patients will be followed from admission until discharge
10 days (avarage time from admission to discharge)
Patient symptom scores on the Functional assessment of chronic illness therapy questionaire
Time Frame: 10 days (avarage time from admission to discharge)
Patients will be followed from admission until discharge
10 days (avarage time from admission to discharge)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mitja Lainscak, MD, PhD, University Clinic Golnik
  • Study Chair: Mitja Kosnik, MD, PhD, contraindications for TCEMS

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2009

Primary Completion (Actual)

June 1, 2009

Study Completion (Actual)

October 1, 2009

Study Registration Dates

First Submitted

October 18, 2010

First Submitted That Met QC Criteria

October 21, 2010

First Posted (Estimate)

October 22, 2010

Study Record Updates

Last Update Posted (Estimate)

April 11, 2013

Last Update Submitted That Met QC Criteria

April 10, 2013

Last Verified

April 1, 2013

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease

Clinical Trials on Transcutaneous electrical muscle stimulation

Subscribe